Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
PALISADE BIO, INC. (PALI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial;
How this was made
The 30-second read
Why it matters
The 8‑K filing provides the first public confirmation of patient dosing in ASCENTRA‑UC and FDA IND clearance for ASCENTRA‑CD, marking key de‑risking steps.
Market read
First‑time disclosure of pivotal trial start and regulatory clearance for a micro‑cap biotech; may attract speculative interest.
What to watch
Cash runway is strong, but dilution risk if additional financing is needed before readouts.
Palisade Bio reports Q3 2026 net loss of $14.6 million as ASCENTRA-UC Phase 2b dosing begins; cash of $113.6 million at September 30, 2026
Clinical execution advanced in the quarter: first ASCENTRA-UC patient dosed October 27, 2026, 29 of 30 planned U.S. sites activated, and FDA IND clearance for ASCENTRA-CD. Operating costs rose sharply from prior-year levels, the net loss widened to $14.6 million from $2.9 million, and cash fell from $133,385 thousand at December 31, 2025 to $113,613 thousand at September 30, 2026. The filing prints no revenue for the quarter and no company guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended Sep 30, 2026GAAP | $10.6M | – | – |
| General and administrative expenses, three months ended Sep 30, 2026GAAP | $5.1M | – | – |
| Total operating expenses, three months ended Sep 30, 2026GAAP | $15.7M | – | – |
| License revenue, three months ended Sep 30, 2026GAAP | — | – | – |
| Loss from operations, three months ended Sep 30, 2026GAAP | −$15.7M | – | – |
| Interest expense, three months ended Sep 30, 2026GAAP | — | – | – |
| Other income, net, three months ended Sep 30, 2026GAAP | $1.08M | – | – |
| Total other income, net, three months ended Sep 30, 2026GAAP | $1.08M | – | – |
| Net loss, three months ended Sep 30, 2026GAAP | $14.6M | – | – |
| Basic and diluted net loss per common share, three months ended Sep 30, 2026GAAP | $(0.07) | – | – |
| Research and development expenses, nine months ended Sep 30, 2026GAAP | $24.38M | – | – |
| General and administrative expenses, nine months ended Sep 30, 2026GAAP | $14.27M | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $38.65M | – | – |
| License revenue, nine months ended Sep 30, 2026GAAP | $500K | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$38.15M | – | – |
| Interest expense, nine months ended Sep 30, 2026GAAP | −$1K | – | – |
| Other income, net, nine months ended Sep 30, 2026GAAP | $3.35M | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | −$34.80M | – | – |
| Basic and diluted net loss per common share, nine months ended Sep 30, 2026GAAP | $(0.16) | – | – |
| Net cash used in operating activities, nine months ended Sep 30, 2026GAAP | −$23.25M | – | – |
| Stock-based compensation and related charges, nine months ended Sep 30, 2026GAAP | $14.15M | – | – |
| Net cash provided by financing activities, nine months ended Sep 30, 2026GAAP | $3.48M | – | – |
| Net decrease in cash, cash equivalents and restricted cash, nine months ended Sep 30, 2026GAAP | −$19.77M | – | – |
| Cash and cash equivalents, as of Sep 30, 2026GAAP | $113.6M | – | – |
| Total assets, as of Sep 30, 2026GAAP | $118.5M | – | – |
| Total stockholders' equity, as of Sep 30, 2026GAAP | $112.4M | – | – |
Capital returns
- No share repurchase or dividend line appears in the filing.
- Proceeds from issuance of common stock were $3,450 thousand for the nine months ended Sep 30, 2026, compared with no such proceeds in the nine months ended Sep 30, 2025 ('—').
- Proceeds from the exercise of warrants were $155 thousand for the nine months ended Sep 30, 2026, compared with $3,909 thousand for the nine months ended Sep 30, 2025.
- Common stock outstanding rose to 174,442,971 shares at Sep 30, 2026 from 159,444,017 shares at Dec 31, 2025, as printed in the balance sheet.
What drove it
- The Company attributes the increase in research and development expenses primarily to advancing PALI-2108 into Phase 2 clinical development, including clinical trial start-up activities, manufacturing and clinical supply, and supporting preclinical and translational research, as well as higher employee-related expenses, including increased non-cash stock-based compensation expense.
- The Company attributes the year-over-year increase in general and administrative expenses to its expanded operating activities and higher employee-related expenses, including increased non-cash stock-based compensation expense.
- Stock-based compensation and related charges were $14,147 thousand for the nine months ended Sep 30, 2026, against $228 thousand in the prior-year period, as printed in the cash flow statement.
- Other income, net was $1,077 thousand for the quarter and $3,350 thousand for the nine months. The filing does not explain its source.
- Development milestones in the period: first ASCENTRA-UC patient dosed October 27, 2026; 29 of 30 planned U.S. sites activated; Health Canada CTA clearance in September 2026; regulatory clearance in the Republic of Georgia in October 2026; FDA IND clearance for ASCENTRA-CD on September 22, 2026.
Concerns
- Net loss was $14.6 million for the quarter, against $2.9 million in the prior-year quarter, and $(34,797) thousand for the nine months, against $(7,882) thousand.
- Total operating expenses were $15,700 thousand for the quarter, against $2,922 thousand in the prior-year quarter, and no revenue line other than $500 thousand of license revenue for the nine months is printed.
- Cash and cash equivalents declined from $133,385 thousand at Dec 31, 2025 to $113,613 thousand at Sep 30, 2026, and the Company's stated runway is tied to readouts in Q4 2027 and Q1 2028.
- The Company's forward-looking statements list the timing of enrollment and site activation, reliance on third parties, the outcome of non-U.S. regulatory reviews, and the need for additional capital as risk factors.
- The filing states that PALI-2108 'has not been approved for any indication' and that the Company's reliance on it is at an early stage of clinical development.
What to watch
- Pace of ASCENTRA-UC enrollment following the first patient dosed on October 27, 2026, and the activation of the remaining site and the approximately 115 total global sites.
- Regulatory decisions on the non-U.S. submissions the Company describes as under review in Europe and other countries.
- Start of enrollment in ASCENTRA-CD, targeted for Q1 2027, and its primary efficacy readout, expected in Q1 2028.
- Operating expense trajectory: nine-month R&D of $24,376 thousand and G&A of $14,270 thousand against the cash balance of $113,613 thousand.
- Topline results from the 12-week induction period of ASCENTRA-UC, expected in Q4 2027.
Balance sheet and cash flow
- Cash and cash equivalents were $113,613 thousand at Sep 30, 2026, against $133,385 thousand at Dec 31, 2025 (balance sheet).
- Restricted cash was $55 thousand at both Sep 30, 2026 and Dec 31, 2025.
- Total liabilities were $6,105 thousand at Sep 30, 2026, against $4,964 thousand at Dec 31, 2025.
- Accumulated deficit was $(187,522) thousand at Sep 30, 2026, against $(152,725) thousand at Dec 31, 2025.
- Net cash used in operating activities for the nine months was $(23,252) thousand, against $(7,703) thousand in the prior-year period.
- Net decrease in cash, cash equivalents and restricted cash for the nine months was $(19,772) thousand, and total cash, cash equivalents and restricted cash ended at $113,668 thousand.
- The Company states that its cash of $113.6 million 'believes will fund operations through key Phase 2 clinical milestones, including the anticipated primary efficacy readouts from ASCENTRA-UC in the fourth quarter of 2027 and ASCENTRA-CD in the first quarter of 2028.'
Analysis
Palisade Bio reported a third quarter 2026 net loss of $14.6 million, or $0.07 per share, against a net loss of $2.9 million, or $0.38 per share, in the third quarter of 2025. Research and development expenses were $10.6 million and general and administrative expenses were $5.1 million, compared with $1.4 million and $1.5 million a year earlier. The filing prints no revenue for the quarter. For the nine months, the Company recorded $500 thousand of license revenue, against none in the prior-year period. The Company attributes the increase in research and development to advancing PALI-2108 into Phase 2 development, including trial start-up, manufacturing and clinical supply, and preclinical and translational work, along with higher employee-related expenses. It attributes the general and administrative increase to expanded operating activities and higher employee-related expenses. Both explanations cite non-cash stock-based compensation, which was $14,147 thousand for the nine months against $228 thousand a year earlier.
The income statement shows the cost base moving from a pre-clinical scale to a Phase 2 scale within twelve months. Total operating expenses were $15,700 thousand for the quarter and $38,646 thousand for the nine months, against $2,922 thousand and $8,075 thousand a year earlier. Other income, net of $1,077 thousand for the quarter, partly offset the operating loss but does not change the direction of the loss. The filing does not provide gross margin, segment data or revenue guidance, because the Company has no commercial product and no segment disclosure.
On the balance sheet, cash and cash equivalents fell to $113,613 thousand at September 30, 2026 from $133,385 thousand at December 31, 2025. Net cash used in operating activities was $(23,252) thousand for the nine months, against $(7,703) thousand a year earlier. Financing activities provided $3,480 thousand, mainly from $3,450 thousand of common stock issuance. Total stockholders' equity was $112,440 thousand and the accumulated deficit reached $(187,522) thousand. The Company states that its cash will fund operations through the ASCENTRA-UC readout in the fourth quarter of 2027 and the ASCENTRA-CD readout in the first quarter of 2028, but the filing does not give a quantified cash runway.
Clinically, the period was defined by execution. The first ASCENTRA-UC patient was dosed on October 27, 2026, with 29 of 30 planned U.S. sites activated and global expansion toward approximately 115 sites. The IND for ASCENTRA-CD was cleared by the FDA on September 22, 2026, with enrollment targeted for Q1 2027. Five posters at ACG 2026 and additional presentations at UEG Week 2026 were disclosed, but the filing describes the Phase 1b data as exploratory and open-label in five patients. Those findings are presented as support for continued development rather than as efficacy results.
For investors, the central questions are the pace of ASCENTRA-UC enrollment against the approximately 204-patient target, the conversion of planned non-U.S. regulatory submissions, and whether operating spending stays within the cash balance through the stated readouts. The quarter's numbers show the step-up in spending that the Phase 2 program requires, with no revenue offset and no company guidance to compare against.
Management, verbatim
With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress
JD Finley, Chief Executive Officer
Our strong financial position supports execution across both programs as we work to establish PALI-2108's potential as a differentiated, once-daily oral treatment for patients living with IBD.
JD Finley, Chief Executive Officer
Now that ASCENTRA-UC is underway, our priority is to maintain enrollment momentum and deliver the clinical data needed to establish PALI-2108's potential in ulcerative colitis
Mitch Jones, M.D., Ph.D., President and Chief Medical Officer
Not in the filing
stated, not guessed- No company financial guidance is provided, so the guidance field and vs_prior_guidance are null and empty.
- The filing does not print year-over-year or quarter-over-quarter percentage changes for any line, so all change fields are null.
- No prior-quarter (June 30, 2026) figures are printed, so all prior_quarter fields are null.
- The filing reports no segments or product lines, so segments is empty.
- Prior-year-end balances (December 31, 2025) are printed on the balance sheet but are not a year-earlier comparison for the cash, total assets and equity rows, so those prior fields are null.
- The filing does not state a quantified cash runway in months or years.
- The filing does not provide a free cash flow line or a non-GAAP measure.
- The filing does not print consensus estimates or the share price reaction, so neither is included.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Palisade Bio (Nasdaq: PALI) is a clinical‑stage company developing oral PDE4 inhibitor PALI‑2108 for ulcerative colitis and Crohn's disease.
Ticker impact
SEC 8‑K reports Q3 2026 results and initiates Phase 2b ASCENTRA‑UC trial with first patient dosed, plus FDA IND clearance for Phase 2a ASCENTRA‑CD.
potential upside as investors price in trial progress; downside risk if enrollment slows or data miss expectations
New clinical milestones and cash runway are material for a micro‑cap biotech; market typically reacts to trial initiations.
Market effects
Adds momentum to the IBD biotech sub‑sector, may lift peers with similar pipelines.
Limited to US biotech investors; no broader regional effect.
Modest; primarily of interest to specialty pharma traders.
Counterpoint
Trial initiation does not guarantee success; investors may overprice future data.
Key entities
- ExecutiveJD Finley
CEO of Palisade Bio, quoted on trial progress.
- ExecutiveMitch Jones, M.D., Ph.D.
President and CMO, discussed clinical milestones.
